Nipocalimab Biosimilar – Anti-FCGRT mAb – Research Grade from ProteoGenix; catalogue PX-TA1690; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Nipocalimab Biosimilar – Anti-FCGRT mAb – Research Grade: A Revolutionary Antibody Nipocalimab Biosimilar, also known as Anti-FCGRT mAb, is a groundbreaking antibody that has the potential to revolutionize the field of therapeutics. This biosimilar is a monoclonal antibody that specifically targets the FCGRT protein, making it a highly specific and effective therapeutic agent.
Nipocalimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody. It is composed of two heavy chains and two light chains, making it a Y-shaped molecule. The heavy chains consist of four constant regions (CH1, CH2, CH3, and CH4) and one variable region (VH). The light chains consist of one constant region (CL) and one variable region (VL). These variable regions are responsible for the specific binding to the FCGRT protein.
The main activity of Nipocalimab Biosimilar is its ability to bind to the FCGRT protein. FCGRT, also known as neonatal Fc receptor, is a protein that plays a crucial role in the recycling of immunoglobulin G (IgG) antibodies in the body. By binding to FCGRT, Nipocalimab Biosimilar blocks the recycling of IgG antibodies, leading to a decrease in their levels in the body. This, in turn, can have a therapeutic effect on various diseases.
Nipocalimab Biosimilar has shown promising results in preclinical studies for the treatment of various diseases. Its main application is in the treatment of autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis. By reducing the levels of IgG antibodies, Nipocalimab Biosimilar can help alleviate the symptoms of these diseases and improve the overall health of patients.
Additionally, Nipocalimab Biosimilar has also shown potential in the treatment of cancer. By targeting the FCGRT protein, it can enhance the body’s immune response against cancer cells and potentially improve the efficacy of other cancer therapies.
Nipocalimab Biosimilar has several advantages over traditional therapies. Firstly, its highly specific binding to the FCGRT protein minimizes the risk of off-target effects and reduces the potential for adverse reactions. Secondly, as a biosimilar, it is a more cost-effective option compared to other monoclonal antibodies on the market. Finally, its potential to treat a wide range of diseases makes it a versatile and valuable therapeutic agent.
The future of Nipocalimab Biosimilar looks promising, with ongoing clinical trials in various autoimmune diseases and cancer. If successful, it has the potential to become a game-changer in the field of therapeutics, providing a more targeted and cost-effective treatment option for patients.
Nipocalimab Biosimilar, also known as Anti-FCGRT mAb, is a highly specific and effective antibody that targets the FCGRT protein. Its potential to treat various diseases, along with its cost-effectiveness, make it a promising therapeutic option for patients. With ongoing research and clinical trials, Nipocalimab Biosimilar has the potential to revolutionize the field of therapeutics and improve the lives of many individuals.
ProteoGenix catalogue number PX-TA1690. For research use only.
Target: Nipocalimab Biosimilar – Anti-FCGRT mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg, 10mg, 25mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Nipocalimab Biosimilar – Anti-FCGRT mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
